These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 12973747)

  • 1. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W; Parsons CG
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG; Stöffler A; Danysz W
    Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM
    Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.
    Danysz W; Parsons CG; Mobius HJ; Stoffler A; Quack G
    Neurotox Res; 2000; 2(2-3):85-97. PubMed ID: 16787834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
    Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia.
    Müller WE; Mutschler E; Riederer P
    Pharmacopsychiatry; 1995 Jul; 28(4):113-24. PubMed ID: 7491365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
    Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
    Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats.
    Morè L; Gravius A; Nagel J; Valastro B; Greco S; Danysz W
    Behav Pharmacol; 2008 Oct; 19(7):724-34. PubMed ID: 18797249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
    Kornhuber J; Weller M
    Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
    Kornhuber J; Weller M
    Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of memantine.
    Johnson JW; Kotermanski SE
    Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical relevance of memantine use].
    Sobów T
    Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS; Rauw G; Baker GB; Kar S
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine.
    Gilling KE; Jatzke C; Parsons CG
    Neuropharmacology; 2007 Sep; 53(3):415-20. PubMed ID: 17632186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.